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BACKGROUND AND PURPOSE
Opioid δ receptor agonists are potent antihyperalgesics in chronic pain models, but tolerance develops after prolonged use.
Previous evidence indicates that distinct forms of tolerance occur depending on the internalization properties of δ receptor
agonists. As arrestins are important in receptor internalization, we investigated the role of arrestin 2 (β-arrestin 1) in mediating the
development of tolerance induced by high- and low-internalizing δ receptor agonists.
EXPERIMENTAL APPROACH
We evaluated the effect of two δ receptor agonists with similar analgesic potencies, but either high-(SNC80) or low-(ARM390)
internalization properties in wild-type (WT) and arrestin 2 knockout (KO) mice. We compared tolerance to the antihyperalgesic
effects of these compounds in a model of inflammatory pain. We also examined tolerance to the convulsant effect of SNC80.
Furthermore, effect of chronic treatment with SNC80 on δ agonist-stimulated [35S]-GTPγS binding was determined in WT and KO
mice.
KEY RESULTS
Arrestin 2 KO resulted in increased drug potency, duration of action and decreased acute tolerance to the antihyperalgesic effects
of SNC80. In contrast, ARM390 produced similar effects in both WT and KO animals. Following chronic treatment, we found a
marked decrease in the extent of tolerance to SNC80-induced antihyperalgesia and convulsions in arrestin 2 KO mice. Accord-
ingly, δ receptors remained functionally coupled to G proteins in arrestin 2 KO mice chronically treated with SNC80.
CONCLUSIONS AND IMPLICATIONS
Overall, these results suggest that δ receptor agonists interact with arrestins in a ligand-specific manner, and tolerance to high-
but not low-internalizing agonists are preferentially regulated by arrestin 2.
Abbreviations
ARM390, N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide; CFA, complete Freund’s adjuvant; KO, knockout;
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Introduction
The opioid δ receptors, also known as δOR, are GPCRs that
play an important role in the regulation of pain processing
and emotional responses (Gaveriaux-Ruff et al., 2011;
Pradhan et al., 2011). Recently, δ receptor agonists have
attracted increasing research interest as a potential alterna-
tive to μ receptor agonists (Gendron et al., 2016). Compared
to μ receptor agonists, δ receptor agonists are poor analgesics
for acute pain (Gallantine and Meert, 2005), but they are
highly effective in models of chronic pain. This difference
in antinociceptive efficacy is likely due to increased function-
ality of δ receptors during chronic pain states (Fraser et al.,
2000; Hurley and Hammond, 2000; Cahill et al., 2003; Kabli
and Cahill, 2007; Gaveriaux-Ruff et al., 2008; Pradhan et al.,
2013). Unlike μ receptor agonists, δ receptor agonists do not
show significant abuse liability (Negus et al., 1998; Brandt
et al., 2001; Stevenson et al., 2005) and lack several side effects
associated with μ receptor activation (constipation, respira-
tory depression, etc.) (Gallantine and Meert, 2005). However,
some δ receptor agonists can cause convulsions, which has
limited their clinical development (Comer et al., 1993; Broom
et al., 2002a). In addition, prolonged exposure to δ or μ recep-
tor agonists leads to the development of tolerance, which
hinders their therapeutic use.
The extent and duration of GPCR signalling are governed
by multiple factors, including receptor desensitization, inter-
nalization, down-regulation and recycling. Arrestins are key
regulators of GPCR desensitization and internalization
(Luttrell and Lefkowitz, 2002; Reiter et al., 2012). In addition,
arrestins act as multifunctional scaffolding proteins and sig-
nalling intermediates with effects on cytoskeletal remodel-
ling (Mittal et al., 2013), protein ubiquitination (Shenoy,
2014), trafficking of ion channels (Nagi et al., 2015) and gene
transcription (Ma and Pei, 2007). Similar to many GPCRs,
ligand-activated δ receptors are also modulated by arrestins
(Lowe et al., 2002; Zhang et al., 2005; Qiu et al., 2007;
Raehal and Bohn, 2011). In cellular models, both arrestin 2
(β-arrestin 1) and arrestin 3 (β-arrestin 2) can mediate δ recep-
tor desensitization and internalization after receptor phos-
phorylation (Qiu et al., 2007; Hong et al., 2009).
Interestingly, emerging evidence suggests that arrestins 2
and 3 play distinct roles in downstream functional outcomes
upon GPCR activation (Taylor et al., 2016). In line with this
functional specialization of arrestin isoforms, δ receptor ex-
port from the Golgi to the cell surface is selectively regulated
by arrestin 2 through the RhoA/ROCK/LIMK pathway (Mittal
et al., 2013). To add one more layer of complexity, several
studies have demonstrated the existence of agonist-specific
recruitment of arrestin isoforms at many GPCRs, including
the δ receptor. Inmouse embryonic fibroblasts, DPDPE prefer-
entially recruited arrestin 3 to induce phosphorylation-
dependent δ receptor internalization (Qiu et al., 2007). In
contrast, arrestin 2 mediated etorphine-activated δ receptor
internalization in SK-N-BE cells, while facilitating receptor
desensitization, but not internalization, in response to
DPDPE or deltorphin I (Bowman et al., 2015). Recently, we
reported that in vivo, the binding of the high-internalizing
agonist SNC80 produces preferential interaction between δ
receptors and arrestin 2, and low-internalizing agonists like
ARM390 or JNJ20788560 preferentially promote arrestin 3-
receptor interactions (Pradhan et al., 2016). An increased
interaction between the δ receptor and arrestin 3 facilitated
receptor resensitization and protected against the develop-
ment of behavioural tolerance to low-internalizing agonists
(Pradhan et al., 2016).
In the present study, we explored the long-term behav-
ioural consequences of the ligand-specific interaction be-
tween arrestin 2 and δ receptors using SNC80 and ARM390.
We found that arrestin 2 mediates the development of toler-
ance to the antihyperalgesic and convulsive effects of
SNC80, but not tolerance to the antihyperalgesic effects of
ARM390. Furthermore, assays monitoring receptor function
ex vivo after the establishment of tolerance to SNC80 revealed
that δ receptors remain functionally coupled to G proteins in
the absence of arrestin 2. These studies demonstrate that the
ligand-selective recruitment of arrestins by δ receptor ago-




Animal studies are reported in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015)
and the US National Research Council’s Guide for the Care
andUse of Laboratory Animals. Mice were group-housed with
a maximum of five animals per cage in clear polypropylene
cages with corn cob bedding and nestlets as enrichment.
Arrestin 2 knockout (KO) mice were generously provided
by R. Lefkowitz (Duke University). Both male and female
mice were used. Mice, aged 8–20 weeks, were housed in a
temperature- and humidity-controlled animal colony on a
12 h light/dark cycle. Mice had free access to food and
water at all times. All animal experiments were performed
according to Association for Assessment and Accreditation
of Laboratory Animal Care guidelines as administered
by the University of Illinois at Chicago and University of
Michigan Animal Care Committees. A total of 242 mice
were used in these experiments – 118 wild-type (WT) and
124 arrestin 2 KO.
Drugs
All drugs were administered in a volume of 10 mL·kg1. SNC80
(Tocris Bioscience, Pittsburgh, PA, USA) was dissolved in acidic
0.9% saline, pH 5.5, and injected i.p. ARM390 (AstraZeneca,
R&D,Wilmington, DE, USA)was dissolved in dH2O and admin-
istered by oral gavage. Unless otherwise stated, mechanical
sensitivity was tested 45 min after treatment with SNC80 or
ARM390. All other drugs were purchased from Sigma-Aldrich
(St. Louis, MO, USA), unless noted otherwise.
Inflammatory pain model
The complete Freund’s adjuvant (CFA)-induced inflamma-
tory pain model was performed as described previously
(Pradhan et al., 2016; Vicente-Sanchez et al., 2016). Briefly,
inflammation was induced by injecting 13 μL of CFA
(Sigma-Aldrich) into the plantar surface of the hindpaw, and
animals were tested 72 h after injection. Mice were habitu-
ated to the testing area for 20 min daily for 2 days before
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baseline testing. The threshold for mechanical responses of
the hindpaw to punctate mechanical stimuli (mechanical
hyperalgesia) was assessed according to the up-and-down
method (Chaplan et al., 1994). A series of eight von Frey fila-
ments with bending force ranging from 0.01 to 2 g was used.
A response was defined as a lifting or shaking of the paw upon
stimulation. Mechanical responses were determined prior to
CFA injection to establish baseline sensitivity. Animals were
randomly assigned to treatment groups, and the experi-
menter was blinded to the drug treatment and/or genotype
when testing.
Observation of SNC80-induced convulsions
Mice were randomized to receive a s.c. injection of SNC80
(3.2, 10, 32 mg·kg1) every 24 ± 1 h for 5 days. Following
SNC80 administration, mice were observed continuously in
individual cages for 30 min for convulsions. Convulsions
were comprised of a tonic phase characterized by sudden
tensing of the musculature and extension of the forepaws
followed by clonic contractions that extended the length of
the body. The severity of each convulsion was quantified
using the following modified Racine scale (Racine, 1972)
adapted from Jutkiewicz et al. (2006): scale 1 – teeth
chattering or face twitching; 2 – head bobbing or twitching;
3 – tonic extension or clonic convulsion lasting less than
3 s; 4 – tonic extension or clonic convulsion lasting longer
than 3 s; 5 – tonic extension or clonic convulsion lasting
more than 3 s with loss of balance. Post-convulsion
catalepsy-like behaviour was assessed by a placing response
in which a horizontal rod was placed under the forearms of
the mouse, and a positive catalepsy score was assigned if the
mouse did not move its forepaws onto the rod or cage floor
within 30 s.
GTPγS assay
Brain membrane preparations were carried out as described
previously (Befort et al., 2001). Animals that were treated
and tested chronically with vehicle or SNC80 for 5 days were
anaesthetised with isoflurane gas and killed by decapitation
24 h after the final treatment day. Whole brains from WT
and KO mice chronically treated and tested with agonist or
vehicle were removed, immediately frozen in isopentane on
dry ice and stored at 80°C prior to use. Whole brain mem-
branes were prepared by homogenizing the brain in ice-cold
0.25 M sucrose solution 10 vol (mL·g1 wet weight of tissue).
Samples were then centrifuged at 1100× g for 10 min. Super-
natants were collected and diluted five times in buffer con-
taining 50 mM Tris-HCl (pH 7.4) and 1 mM EDTA,
following which they were centrifuged at 25000× g for
30 min. The pellets were homogenized in 2 mL ice-cold su-
crose solution (0.32 M), aliquoted and kept at 80°C until
further use.
For the [35S]-GTPγS binding assay, 5 μg of protein was used
per well. Samples were incubated with varying concentra-
tions of SNC80 (105 to 1012 M) for 1 h at 25°C in assay
buffer containing 50 mM Tris HCl (pH 7.4), 3 mM MgCl2,
100 mM NaCl, 0.2 mM EGTA, 30 μM GDP and 0.1 nM [35S]-
GTPγS (Perkin Elmer USA). Incubation was terminated by
rapid filtration and washing in ice-cold buffer (50 mM Tris
HCl, 5 mMMgCl2, 50 mMNaCl, pH 7.4). Bound radioactivity
was quantified using a liquid scintillation counter. Non-
specific binding was defined as binding in the presence of
10 μM GTPγS, and basal binding indicates binding in the ab-
sence of any agonist. Samples were run in triplicate. Plates
were counterbalanced so that different combinations of
groups were represented on a plate, and the experimenter
was blinded to the groups.
Statistical analysis
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015). All data are reported as
mean ± SEM. All graphs were produced in GraphPad Prism
version 6 or 7, and all statistical analysis was performed in
SigmaStat software. Experiments were designed to have an
equal n per group. However, animals were excluded from
analysis if there was an error in drug injection, genotyping
or if they were outliers. Outliers were defined using the
Grubb’s test, and based on this analysis, one data point was
removed from the dataset shown in Figure 3A. In addition,
in the convulsion experiments, arrestin 2 KO mice died or
were killed following 32 mg·kg1 SNC80; and one arrestin 2
KO mouse died due to a misplaced injection that damaged
the liver for the 10 day SNC80 experiment outlined in
Figure 3C. For pain and convulsion experiments, two-way
repeated-measures ANOVAs were performed or where cited
two-way ANOVA was used. For all tests, the level of signifi-
cance αwas set to 0.05. Post hoc analysis was conducted using
a Holm–Sidak post hoc analysis. Post hoc analysis was only per-
formed when F values achieved P< 0.05. For convulsion data,
a Tukey’s post hoc analysis was performed. For the GTPγS as-
says, curve fitting was performed using GraphPad Prism.
SNC80 was fit with a nonlinear fit, one-site model. R2 values
were used to assess goodness of fit. EC50 values were deter-
mined from pooled, fitted data (n = 3–4 mice per group). Each
data point for each mouse was the average of a triplicate, and
this average was considered as n = 1.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al.,
2018), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2017).
Results
Effect of arrestin 2 deletion on the
antihyperalgesic response to SNC80 and
ARM390
To evaluate the role of arrestin 2 in δ receptor-mediated
antihyperalgesia, CFA was injected into the hindpaw, and
72 h later, mice were injected with different doses of SNC80
or ARM390. To assess potential differences in the duration
of drug action, mice were tested 45min (Figure 1A, C) and 3 h
(Figure 1B, D) following injection. In WT mice, SNC80 and
ARM390 produced dose-dependent increases in mechanical
threshold 45 min after administration (Figure 1A, C). After
3 h, SNC80 was no longer effective inWT animals potentially
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due to drug clearance. However, in arrestin 2 KOmice SNC80,
but not ARM390, was enhanced at this time point; and
SNC80 continued to produce significant antihyperalgesic ef-
fects (Figure 1B). ARM390 failed to produce antihyperalgesic
effects in either genotype 3 h post-injection (Figure 1D).
These data show that SNC80, but not ARM390, has increased
efficacy and duration of action in arrestin 2 KO mice.
Effect of arrestin 2 deletion on acute analgesic
tolerance to SNC80 and ARM390
We have previously shown that a single injection of the high-
internalizing δ receptor agonist SNC80 produced acute anal-
gesic tolerance while the low-internalizing agonist ARM390
did not (Pradhan et al., 2009). In those experiments, we tested
Emax doses of drug (10 mg·kg1). Because SNC80 is more
effective in arrestin 2 KO mice than WT mice, we
tested equipotent doses of the drug between the two geno-
types. Thus, KOs received a 3 mg·kg1 dose of SNC80 and
WTs a 10 mg·kg1 dose. For ARM390, both genotypes were
administered a 10 mg·kg1 dose. CFA was injected into the
mouse paw, and severe mechanical hypersensitivity was ob-
served 72 h later (Figure 2, dashed line vs. vehicle controls).
In WT and arrestin 2 KO mice, an initial injection of SNC80
and ARM390 attenuated CFA-induced hyperalgesia (Figure 2,
Injection 1). Consistent with previous findings, a second
injection of SNC80 given 4 h later was ineffective in WT ani-
mals (Figure 2A, Injection 2). However, this acute behavioural
desensitization was not observed in arrestin 2 KO mice
(Figure 2B, Injection 2). A second injection of ARM390 was
equally effective in both WT and KO mice. These results
imply that acute tolerance to SNC80, but not ARM390, is
preferentially mediated by arrestin 2.
Effect of arrestin 2 deletion on the development
of chronic analgesic tolerance to SNC80 and
ARM390
To confirm the role of arrestin 2 in SNC80-induced behav-
ioural tolerance, we examined the consequences of repeated
SNC80 or ARM390 treatment in arrestin 2 WT and KO ani-
mals. WT mice treated daily with SNC80 showed full toler-
ance to the antihyperalgesic effects of SNC80 by the third
day of treatment (Figure 3A). The development of tolerance
to SNC80 was significantly delayed in arrestin 2 KO mice
(Figure 3A). To rule out the possibility that these effects were
Figure 1
Potency and duration of SNC80- or ARM390-induced antihyperalgesia in WT and arrestin 2 KO mice. In a CFA model of inflammatory pain, we
performed a dose- and time-response to SNC80 (i.p.) and ARM390 (p.o.). (A) The antihyperalgesic effect of SNC80 was significantly enhanced
in arrestin 2 KO mice, and the effect of SNC80 was longer lasting in these animals (B), n = 8 per group. Two-way ANOVA with Holm–Sidak post
hoc analysis at both time points, P < 0.05 genotype, dose and interaction; *P < 0.05. (C) ARM390 showed similar effects in arrestin 2 KO and
WT mice (two-way ANOVA, P < 0.05 effect of dose), and regardless of genotype, this antihyperalgesic effect was lost 3 h post-administration
(D), n = 7; vehicle and 10 mg·kg1; n = 9; 1 and 3 mg·kg1. Dashed lines represent baseline mechanical responses assessed pre-CFA injection.
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due to WT and KO mice developing behavioural/associative
tolerance to the assay at different rates, we repeated the same
experiment but tested only on the first and fifth days of
treatment (Figure 3B). Again, SNC80 failed to produce
antihyperalgesic effects in WT animals after repeated treat-
ment, indicating pharmacological tolerance. However, in
arrestin 2 KO mice, the last injection of SNC80 still produced
significant antihyperalgesic effects (Figure 3B). In order to de-
termine if an even longer term treatment would induce phar-
macological tolerance in arrestin 2 KOs, we treated animals
with vehicle or SNC80 daily for 10 days. Even after this
prolonged treatment, SNC80 continued to be effective in
arrestin 2 KO mice as compared to WT controls (Figure 3C).
In contrast to SNC80, WT and arrestin 2 KO mice developed
Figure 2
Acute behavioural tolerance to SNC80 is not observed in arrestin 2 knockout mice. Mechanical responses were determined in the CFA model of
inflammatory pain. Equipotent doses of SNC80 and ARM390 were compared. Injection 1, mechanical responses in (A) WT and (B) arrestin 2 KO
mice treated with vehicle (control, n = 10 per genotype), SNC80 (3 mg·kg1 for KO mice, 13 per group, and 10 mg·kg1 for WT mice, 12 per
group i.p.), or ARM390 (10 mg·kg1, p.o., 12 per genotype). Injection 2, animals re-challenged with the same drug and dose 4 h following In-
jection 1. Dashed lines represent baseline mechanical responses pre-CFA injection. For consistency, all animals were injected i.p. and p.o. Two-
way RM ANOVA for each genotype, P < 0.05 drug, time and interaction for WT; P < 0.05 for drug in KO. *P < 0.05 as compared to Injection
1, Holm–Sidak post hoc analysis. In addition, P < 0.05 when Injection 2 of SNC80 was compared across genotypes; t-test.
Figure 3
The extent of chronic analgesic tolerance after repeated exposure to SNC80 is attenuated in arrestin 2 KO mice. Arrestin 2 WT and KO mice were
injected with equipotent doses of SNC80 (10 mg·kg1 for WT, and 3 mg·kg1 for KO) daily for 5 days, and tested daily, 45 min following each
injection (A, n = 10 per WT group, n = 12 per KO group; two-way RM ANOVA P < 0.05 time, genotype and interaction; *P < 0.05 as compared
to WT-SNC80 group). We also treated mice daily but only tested on the first and the fifth day of treatment (B, n = 8 per group; two-way RM
ANOVA, P < 0.05 genotype × time interaction, *P < 0.05 as compared to day 1, and as compared to WT-SNC80 on day 5); or on the first and
tenth day of treatment (C, n = 5–6 per group; two-way RM ANOVA, P < 0.05 genotype and time). Unlike SNC80, tolerance to repeated
ARM390 treatment was unaltered in arrestin 2 KO mice (D). WT and KO mice were injected with ARM390 (10 mg·kg1, p.o.) daily for 5 days,
and tested 45 min following each injection. n = 6 per group, two-way RM ANOVA P < 0.05 for time only.
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chronic tolerance to the antihyperalgesic effects of ARM390
at similar rates (Figure 3D). Arrestin 2 appears to be necessary
for the development of tolerance to SNC80, but not to the
low-internalizing agonist, ARM390.
The effect of arrestin 2 deletion on tolerance to
SNC80-induced convulsions
To explore the role of arrestin 2 in the development of toler-
ance to other δ receptor-mediated behaviours, tolerance to
SNC80-induced convulsions was evaluated in WT and
arrestin 2 KOmice (Figure 4). ARM390 does not produce con-
vulsions, even at high doses, and therefore was not included
to study the development of tolerance to this phenomenon.
Mice were treated with SNC80 daily for 5 days, and the sever-
ity of convulsions was evaluated using a modified Racine
scale. In WT mice, the dose of 32 mg·kg1 SNC80 was tested
as 10 mg·kg1 does not reliably induce convulsions. SNC80
produced severe convulsive effects on day 1 of treatment,
but failed to produce significant convulsive effects on subse-
quent days in WTs. In contrast, arrestin 2 KO mice exhibited
significant convulsive effects in response to lower doses of
SNC80 (3.2 or 10 mg·kg1), and this effect was observed on
all 5 days. A group of four arrestin 2 KO mice was also tested
with 32 mg·kg1 SNC80. However, on day 1, this dose of
SNC80 produced fatal convulsions in two mice and a
sustained convulsion in a third mouse that prompted the ex-
perimenters to kill it immediately by pentobarbital overdose.
Therefore, this dose of SNC80 was not further evaluated in
arrestin 2 KO animals. Overall, mice lacking arrestin 2
showed increased sensitivity and attenuated tolerance to
SNC80-induced convulsive effects.
The effect of arrestin 2 deletion on G
protein-coupling to δ receptors after chronic
exposure to SNC80
We then investigated receptor functionality of δ receptors af-
ter the establishment of tolerance to SNC80. Arrestin 2 WT
and KO animals were injected and tested with vehicle or
equipotent doses of SNC80 (10 mg·kg1 WT, 3 mg·kg1 KO)
once daily for 5 days, and tissue was collected 24 h after the
final treatment day. SNC80-induced G protein-coupling to δ
receptors was examined in brain membrane preparations.
[35S]GTPγS binding was severely attenuated in the brains of
WT animals treated repeatedly with SNC80, in line with the
observed chronic tolerance observed in these animals. In con-
trast, SNC80-treated arrestin 2 KO mice showed [35S]GTPγS
binding that was comparable to SNC80-naïve controls
(Figure 5A, B). These results indicate that in arrestin 2 KO
mice δ receptor-G protein coupling is preserved, even after
chronic treatment with SNC80.
Discussion
In this study, we examined the role of arrestin 2 in the devel-
opment of tolerance to the behavioural effects of a high-
(SNC80) or a low- (ARM390) internalizing δ receptor agonist.
We found that KO of arrestin 2 results in increased efficacy
and duration of action of the antihyperalgesic effects of
SNC80 and increased the potency of SNC80 to produce con-
vulsions. Loss of arrestin 2 also attenuated the development
of tolerance to both the antihyperalgesic and convulsive ef-
fects of chronic SNC80 treatment. Although some chronic
tolerance to the antihyperalgesic effects of SNC80 was ob-
served, it was considerably diminished and was significantly
dependent on repeated testing (behavioural/associative toler-
ance). In accordance with these findings, δ receptors in KO
mice treated chronically with SNC80 remained functionally
coupled to G proteins, an effect not observed in the WTs. In
contrast, the low-internalizing agonist ARM390 produced
similar analgesic effects and tolerance in both WT and KO
arrestin 2 animals. Overall, these results suggest a ligand-
selective recruitment of arrestins by different δ receptor ago-
nists and reveal that SNC80 may preferentially recruit
arrestin 2 to promote tolerance whereas ARM390 does not.
We have previously shown that loss of arrestin 2 en-
hances the antihyperalgesic effects of SNC80 and inhibits
the development of acute tolerance (Pradhan et al., 2016).
This study reproduce those results in another group of ani-
mals and also demonstrate a potential role for arrestin 2 in
regulating the development of tolerance to chronic daily ad-
ministration of SNC80. After repeated administration, a
marked reduction in tolerance to the antihyperalgesic effects
of SNC80 was clear in arrestin 2 KO animals tested only twice,
at the beginning and end of a 5- or 10-day treatment, but not
in animals tested every day. A previous study showed that re-
peated testing of mice treated with vehicle for 5 days resulted
in a 50% decrease of the analgesic effects of a subsequent
challenge with SNC80 or ARM390 (Pradhan et al., 2010).
It is known that environmental cues and processes related
Figure 4
Development of tolerance to the convulsive effects of SNC80 is at-
tenuated in arrestin 2 KOmice. The severity of convulsions produced
by acute administration of SNC80 in WT mice (32 mg·kg1) or
arrestin 2 KO mice (3.2 or 10 mg·kg1) did not differ significantly.
In WT mice, SNC80 failed to produce significant convulsive effects
after the first day of treatment. Repeated daily administration of
SNC80 produced significant convulsive effects in arrestin 2 KO mice
on all test days. For all groups n = 6, two-way RM ANOVA, P < 0.05
time, group and interaction. *P < 0.05 compared to same treatment
group on day 1, #P < 0.05 compared to the WT group on the same
day.
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to memory and learning can facilitate tolerance develop-
ment during repeated exposure to opioids (Gamble and
Milne, 1989; Mitchell et al., 2000). Thus, our data demon-
strate that the tolerance that develops to SNC80-induced
antihyperalgesia in arrestin 2 KOs is significantly depen-
dent on associative learning. Our data also show that the
development of tolerance to the convulsive effects of
SNC80 was attenuated in arrestin 2 KO mice, suggesting
that arrestin 2 is also an important regulator of this
behaviour. Although seizure activity can have profound ef-
fects on behaviour, it is unlikely to have affected
antihyperalgesic responses to SNC80, as convulsive effects
are lost within 10–15 min post-administration (Broom et al.,
2002a). In addition, the arrestin 2 KOs developed
behavioural/associative tolerance similar to WTs, suggest-
ing that their learning and memory was not affected. Loss
of δ receptor in GABAergic forebrain neurons was sufficient
to block all SNC80-induced seizurogenic activity (Chung
et al., 2015). It remains to be seen whether arrestin 2 acts
as a negative regulator of δ receptor-mediated convulsions
within these neurons. Furthermore, the role these neurons
play in the development of tolerance to SNC80-induced
convulsions should be examined. Taken together, these be-
havioural results also imply that both central (convulsions)
and peripheral (antihyperalgesia) effects of SNC80 are regu-
lated by arrestin 2.
Tolerance to the convulsive effects of SNC80 developed
rapidly relative to antihyperalgesic tolerance, and almost no
convulsions were observed in WT mice in the second day of
SNC80 treatment. These results are in keeping with a previ-
ous report that showed that tolerance to the convulsive ef-
fects of SNC80 developed faster than tolerance to its
antidepressant-like effects and that this rapid tolerance
corresponded with differential tolerance rates in δ receptor
signalling (Jutkiewicz et al., 2005). One hypothesis is that δ re-
ceptor agonists have a low efficacy requirement to produce
convulsive effects, as compared to their pain-relieving prop-
erties (Broom et al., 2002b).
Consistent with the in vivo data, our GTPγS assays re-
vealed that δ receptors remain functionally coupled to G
proteins in arrestin 2 KO mice repeatedly treated with
SNC80. SNC80 has been shown to induce robust δ receptor
internalization in vitro and in vivo (Lecoq et al., 2004;
Scherrer et al., 2006; Pradhan et al., 2009, 2010; Charfi
et al., 2014). This loss of surface δ receptor expression likely
accounts for the decreased δ receptor function observed af-
ter repeated administration of SNC80 to WT mice. Follow-
ing prolonged agonist exposure, internalized δ receptors
are targeted to lysosomes and degraded (Ko et al., 1999;
Tsao and von Zastrow, 2000; Whistler et al., 2002), a process
that is also induced after chronic treatment with SNC80
(Lecoq et al., 2004; Pradhan et al., 2010). This receptor
Figure 5
Arrestin 2 KO mice showed intact G protein-δ receptor coupling after chronic SNC80 treatment. Graphs show (A) concentration–response curves
for SNC80-induced [35S]-GTPγS binding and (B) Emax values calculated from these responses. The y-axis shows mean ± SEM specific [35S]-GTPγS
binding expressed as percentage basal binding; n = 3 mice per group.
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down-regulation results in generalized tolerance to all the
behavioural effects triggered by SNC80 (Pradhan et al.,
2010). Because arrestin 2 is involved in δ receptor internal-
ization (Zhang et al., 2005, 2008; Qiu et al., 2007; Mittal
et al., 2013), the increased analgesic effects of SNC80 and
decreased tolerance observed in the absence of arrestin 2
could be due to diminished receptor internalization. There-
fore, more δ receptors would be accessible to SNC80 resulting
in increased receptor activation.Mittal et al. (2013) found that
loss of arrestin 2 increased the export of δ receptors to the cell
membrane in response to SNC80 via a deregulation of the
ROCK-LIMK pathway. This enhancement of agonist-induced
externalization could also account for the differences ob-
served in the behavioural effects of SNC80 in arrestin 2 KOs.
We hypothesize that our findings could result from a combi-
nation of both phenomena, a decrease in receptor internaliza-
tion along with an increase in δ receptors externalization,
thus resulting in a net enhancement of SNC80 effects.
Unlike SNC80, the antihyperalgesic effects of ARM390
were not altered in arrestin 2 KO mice. Previous BRET studies
demonstrated that the low-internalizing agonist ARM390 re-
cruits arrestin 2 at the δ receptor; however, no changes in the
antihyperalgesic effects of ARM390 were observed in KOs of
arrestin 2 (Pradhan et al., 2016). Moreover, no significant dif-
ferences in the development of acute and chronic tolerance
to ARM390 were detected between arrestin 2 KOs and WT
animals. Importantly, the mechanisms involved in the devel-
opment of tolerance to SNC80 and ARM390 are different.
ARM390 does not promote robust receptor endocytosis,
and animals treated with ARM390 do not develop acute anal-
gesic tolerance (Pradhan et al., 2010; Pradhan et al., 2016). In
addition, chronic tolerance to ARM390 is independent of
receptor internalization and relies on cellular adaptations oc-
curring down-stream of the receptor (Pradhan et al., 2010).
Thus, contrary to SNC80, recruitment of arrestin 2 at
ARM390-activated δ receptors may serve a different function
to the traditional role of arrestins as attenuators of GPCR
signalling.
Numerous lines of evidence in vitro indicate that SNC80-
activated δ receptors recruit both arrestin 2 and arrestin 3
(Cen et al., 2001; Audet et al., 2012; Mittal et al., 2013;
Chiang et al., 2016; Pradhan et al., 2016). However, our re-
sults suggest functional specialization in vivo for arrestin 2
in modulating the antihyperalgesic effects of SNC80 in the
CFA model of chronic inflammatory pain. Furthermore,
KO of arrestin 3 had no effect on SNC80-induced analgesia
and acute tolerance (Pradhan et al., 2016). Notwithstand-
ing, a recent study has shown a direct correlation between
the efficacy of SNC80 and other δ receptor agonists to in-
duce recruitment of arrestin 3 and increased alcohol con-
sumption (Chiang et al., 2016). Thus, it is a possibility
that our results are specific to regions controlling pain pro-
cessing and convulsions and that arrestin 3 may play an
important role in regulation of SNC80-activated δ receptor
in other CNS areas. Further work will be needed to explain
potential regional differences in agonist-specific receptor-
arrestin interactions.
These results suggest that arrestin 2 differentially regu-
lates δ receptor effects in an agonist-dependent manner. The
ligand-specific recruitment of arrestins observed in our stud-
ies is likely due to distinct conformational changes induced
by the binding of different δ receptor agonists. The δ receptor
agonists induce specific receptor conformations that possess
different affinities for arrestins, resulting in distinct receptor
desensitization, internalization and signalling profiles that
ultimately dictate physiological outcomes (Aguila et al.,
2012; Audet et al., 2012). In BRET studies, it has been shown
that agonists like SNC80 stabilize a δ receptor conformation
in which its C-terminal tail becomes closer to Gβγ subunits.
This spatial rearrangement of the receptor increased the sta-
bility of its interaction with arrestin 3 and caused poor
recycling and marked receptor desensitization (Audet et al.,
2012). Differentially, the δ receptor agonist DPDPE moved
the C-terminal tail of the δ receptor away from Gβγ subunits
and promoted a transient interaction with arrestin 3 that re-
sulted in receptor recycling and sustained analgesia (Audet
et al., 2012). These studies support the notion that agonists
for the same receptor can promote distinct receptor–arrestin
complexes.
Our study indicates that arrestin 2 may be selectively re-
cruited in vivo by high-internalizing δ agonists to modulate
chronic pain. The specific deletion of arrestin 2 produced
enhanced δ receptor function to the high-internalizing
agonist SNC80 even after chronic treatment but did not
modify the behavioural effects to the low-internalizing
agonist ARM390. Collectively, our results demonstrate the
behavioural significance that ligand-specific interactions
between arrestin 2 and the δ receptor may have and reveal a
potential role of arrestin 2 as a mediator of the analgesic
effects and tolerance to high-internalizing δ receptor agonist.
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